Bayer to acquire Asklepios BioPharmaceutical for up to $4bn
As per terms of the deal, Asklepios will secure an upfront consideration of $2bn and potential success-based milestone payments of up to $2bn from Bayer. Based in North
PMM is a complex mitochondrial disease in which genetic mutations mainly impair the function of mitochondria that may result in reduced muscle function, reduced endurance to exercise, increased
The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative